New hope for Alzheimer's pain: opioid combo trial launches

NCT ID NCT07323914

Recruiting now Symptom relief Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial at Xuanwu Hospital in Beijing is testing whether a combination painkiller (oxycodone/acetaminophen) can safely ease chronic pain in 10 people with Alzheimer's disease. Participants will take the medication once daily for 12 weeks, with pain levels and side effects checked at several points. The goal is to find a better way to manage pain in patients who often cannot communicate their discomfort clearly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oxycodone/acetaminophen (Tylex)
What this could lead to: If successful, this could provide a safe and effective way to manage chronic pain in people with Alzheimer's disease, improving their comfort and quality of life.
What could go wrong: This is a very small trial with only 10 participants, so results may not apply to everyone. Opioids carry risks like drowsiness, falls, and dependence, especially in older adults with dementia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Chronic Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Xuanwu Hospital, Capital Medical University
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.